A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Fasinumab (Primary)
- Indications Back pain; Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT CLBP 1
- Sponsors Regeneron Pharmaceuticals
- 17 Aug 2018 Planned End Date changed from 2 Apr 2019 to 1 May 2019.
- 17 Aug 2018 Planned primary completion date changed from 21 Aug 2018 to 22 Aug 2018.
- 29 Jun 2018 This trial has been discontinued in Spain.